New study tests drug interactions in opiate recovery patients
NCT ID NCT07314346
First seen Jan 11, 2026 · Last updated Jun 13, 2026 · Updated 23 times
Summary
This study looks at how a new experimental drug combination (BEM/RZR) changes the levels of common opiate withdrawal medications (buprenorphine/naloxone or methadone) in the blood. It involves 32 healthy volunteers who are already on stable therapy for opiate withdrawal. The goal is to see if the drugs interact, helping doctors adjust doses safely in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER STUDY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atea Study Site
RECRUITINGHollywood, Florida, 33019, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Atea Study Site
RECRUITINGOverland Park, Kansas, 66212, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Atea Study Site
RECRUITINGMarlton, New Jersey, 08053, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.